Neuberg Center For Genomic Medicine Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 27-10-2024
- Paid Up Capital ₹ 1.50 Cr
as on 27-10-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 201.33%
(FY 2023)
- Profit 216.63%
(FY 2023)
- Ebitda 450.89%
(FY 2023)
- Net Worth 180.69%
(FY 2023)
- Total Assets 37.45%
(FY 2023)
About Neuberg Center For Genomic Medicine
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Athmanathan Ganesan and Sandip Shah serve as directors at the Company.
- CIN/LLPIN
U85200TN2021PTC144003
- Company No.
144003
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jun 2021
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Neuberg Center For Genomic Medicine?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Athmanathan Ganesan  | Director | 09-Jun-2021 | Current |
| Sandip Shah | Director | 09-Jun-2021 | Current |
Financial Performance of Neuberg Center For Genomic Medicine.
Jeenomics Laboratory Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 201.33% increase. The company also saw a substantial improvement in profitability, with a 216.63% increase in profit. The company's net worth Soared by an impressive increase of 180.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neuberg Center For Genomic Medicine?
In 2023, Neuberg Center For Genomic Medicine had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Neuberg Abha Laboratory Private LimitedActive 4 years 7 monthsAthmanathan Ganesan and Sandip Shah are mutual person
Magnum Imaging & Diagnostics Private LimitedActive 11 years 3 monthsAthmanathan Ganesan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neuberg Center For Genomic Medicine?
Neuberg Center For Genomic Medicine has a workforce of 23 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neuberg Center For Genomic Medicine, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neuberg Center For Genomic Medicine's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
